Actavis Sues FDA Over Generic of Pfizer’s Celebrex

Generics producer Actavis has sued the U.S. Food and Drug Administration, challenging its decision to award exclusive rights to Israel's Teva to sell a generic version of Pfizer's blockbuster painkiller Celebrex.

The move follows a similar lawsuit announced earlier by another generics producer Mylan.

On Apr. 17, Teva signed a deal that allows it to launch a generic version of Celebrex in December. The agreement came after a U.S. court in March invalidated a patent extending Pfizer's marketing exclusivity for the drug to Dec. 2, 2015.

Celebrex's basic chemical patent is now set to expire next month, as planned. Pfizer, however, has said it will continue to defend the patent extending its exclusivity.

The FDA usually grants 180 days of marketing exclusivity to drugmakers who are first to file for generic approvals. Teva, the world's largest generic producer said it believed it was the first to file for an approval for Celebrex.

The Pfizer drug, which is used to treat arthritis pain and inflammation, generated about $2.92 billion in sales in 2013, according to the company's annual regulatory filing.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.